Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell tags : Biotechnology save search
Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Published: 2023-09-27 (Crawled : 14:00) - biospace.com/
ACET | $2.155 -2.05% 23K
|
Health Technology
|
| O: 0.7%
H: 4.86%
C: 0.0%
cancer cell immunotherapy meeting platform
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma
Published: 2023-02-23 (Crawled : 15:00) - biospace.com/
BCAB | $2.77 -3.15% 130K
|
|
| O: -0.63%
H: 2.22%
C: -8.25%
ba3182 treatment fda clearance drug t-cell application
Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)
Published: 2023-01-26 (Crawled : 15:00) - biospace.com/
COYA | $8.37 5.1K
|
|
| O: -3.77%
H: 3.69%
C: 0.22%
treatment disease preclinical animal alzheimer’s potential
Kuick Research Recognizes TC BioPharm as a Key Player in the Gamma-Delta T Cell Therapy Market
Published: 2022-05-23 (Crawled : 15:00) - biospace.com/
TCBP | $1.61 23K
|
|
| O: 11.61%
H: 0.0%
C: -5.6%
research therapy market
Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch
Published: 2022-05-17 (Crawled : 18:00) - biospace.com/
ZSAN | $0.5576 7.23% -5.85%
|
Health Technology
|
| O: 2.72%
H: 7.32%
C: 6.88%
covid-19 vaccine
Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal
Published: 2022-04-13 (Crawled : 16:00) - biospace.com/
ALLO | $3.505 -1.27% 110K
|
Health Technology
|
| O: 0.47%
H: 3.04%
C: 2.46%
allo-316 treatment research preclinical renal therapeutics cancer pre-clinical cell carcinoma
Research Roundup: How COVID-19 Vaccines Train T Cells and More Research News
Published: 2022-01-28 (Crawled : 13:00) - biospace.com/
JNJ | $144.84 -1.86% 3M
|
Health Technology
|
| O: 0.16%
H: 0.57%
C: 0.54%
covid-19 research covid cel vaccine t-cell train
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
ALLO | $3.505 -1.27% 110K
|
Health Technology
|
| O: 1.05%
H: 2.52%
C: -22.56%
allo-715 ema therapeutics positive results phase 1 positive therapy results t-cell
Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy
Published: 2021-12-06 (Crawled : 14:30) - biospace.com/
ACET | $2.155 -2.05% 23K
|
Health Technology
|
| O: 39.29%
H: 0.0%
C: 0.0%
positive therapy
Cabaletta Bio Announces Presentation of Preclinical Data Supporting PLA2R-CAART as a Potential Precision Therapy for Antigen-Specific B Cell Depletion in PLA2R Membranous Nephropathy at ASN Kidney Week 2021
Published: 2021-10-15 (Crawled : 21:00) - biospace.com/
CABA | $16.085 -0.59% 51K
|
Health Technology
|
| O: -0.24%
H: 1.06%
C: 0.33%
presentation potential therapy nephropathy preclinical kidney t-cell pre-clinical
Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma
Published: 2021-07-01 (Crawled : 12:00) - biospace.com/
DTIL | $13.06 3.7K
|
Health Technology
|
| O: 1.04%
H: 1.74%
C: 0.08%
phase 1 trial car-t
Second Genome Presents Data at the World Microbe Forum Demonstrating Application of its Computational Platform sg-4-sight to Identify Peptides that Have the Potential to Modulate T Cell Activity in Inflammatory Bowel Disease (IBD)
Published: 2021-06-22 (Crawled : 12:00) - biospace.com/
GILD | $67.36 -0.58% 700K
|
Health Technology
|
| O: -0.17%
H: 0.54%
C: -0.28%
disease potential computational t-cell
Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company
Published: 2021-06-22 (Crawled : 12:00) - biospace.com/
BX | $120.23 -0.78% 450K
|
Finance
|
| O: 0.0%
H: 1.06%
C: 0.1%
SNY | $45.99 0.13% 70K
|
Health Technology
|
| O: -0.57%
H: 0.25%
C: -0.04%
NTLA | $22.52 -1.75% 160K
|
Health Technology
|
| O: 2.25%
H: 0.49%
C: -2.58%
life science t-cell car-t
ADC Therapeutics’ ZYNLONTA™ (loncastuximab tesirine-lpyl) Added to National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for B-cell Lymphomas
Published: 2021-05-05 (Crawled : 01:00) - biospace.com/
ADCT | $4.44 1.6% 33K
|
Health Technology
|
| O: -0.67%
H: 2.95%
C: -1.79%
cancer t-cell
Gainers vs Losers
| 48% | 52% |
Top 10 Gainers
TPET | $0.4801 107.75% 16M
|
n/a
JAGX | $0.23 93.6% 310M
|
Health Technology
WISA 4 | $3.17 81.14% 36M
|
Electronic Technology
PALI | $7.41 78.13% 14M
|
Manufacturing
SPCB | $0.4278 55.0% 17M
|
Electronic Technology
BTTR | $7.61 49.22% 1.8M
|
Manufacturing
PRSO | $1.79 40.95% 25M
|
Manufacturing
DYNT | $0.5203 40.47% 17M
|
Health Technology
MCBC | $13.755 38.52% 620K
|
Finance
SNGX | $0.5155 33.52% 3.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.